Anti-D immunoglobulin in Rh(D) negative volunteers: clearance of Rh(D) positive red cells and kinetics of serum anti-D levels

被引:12
|
作者
Stucki, M
Schnorf, J
Hustinx, H
Gerber, H
Lerch, PG
Halabi, A
Kleinbloesem, CH
Morell, A
机构
[1] Swiss Red Cross, Blood Transfus Serv, ZLB Cent Lab, CH-3000 Bern 22, Switzerland
[2] Clin Pharma Res AG, Birsfelden, Switzerland
关键词
anti-D; pharmacodynamics; pharmacokinetics; prophylaxis; Rh(D) immunization;
D O I
10.1016/S1246-7820(98)80409-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Properties of a new anti-D immunoglobulin were assessed in Rh(D) negative healthy male adults. Six volunteers received intravenous, and five volunteers intramuscular injections of 200 mu g anti-D, 48 hours after pre-treatment with 5 mL of Rh(D) positive erythrocytes. Immediately after intravenous administration of anti-D, a rapid decrease of the Rh(D) positive erythrocytes was noted. After intramuscular injection of anti-D, there was a lag phase of 6 hours until the erythrocytes decreased, and the elimination rate was slower. Twenty-four hours after injection of anti-D, the Rh(D) positive erythrocytes were at the detection limit or no longer detectable in all volunteers. After intravenous administration, anti-D serum levels decreased from 45 ng/mL at two hours to 29 ng/mL at 24 hours, whereas after intramuscular administration, anti-D became detectable at 4 hours and increased to 11 ng/mL at 24 hours. During subsequent months, anti-D serum levels decreased at similar rates in both groups. After six months, anti-D was not detectable in any of the volunteers. Thus, the new anti-D immunoglobulin induced elimination of the Rh(D) positive erythrocytes and suggested that Rh(D) immunization of the volunteers was prevented. (C) Elsevier 1998, Paris.
引用
收藏
页码:180 / 188
页数:9
相关论文
共 50 条
  • [41] Competitive enzyme-linked immunoassay of monoclonal immunoglobulin G anti-D preparations
    Thorpe, SJ
    Fox, B
    Turner, C
    Scott, M
    TRANSFUSION MEDICINE, 2003, 13 (03) : 153 - 159
  • [42] Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia
    Naithani, Rahul
    Kumar, Rajat
    Mahapatra, M.
    Tyagi, Seema
    Saxena, Renu
    PLATELETS, 2009, 20 (07) : 525 - 527
  • [43] Efficacy and Safety of Anti-D for Immune Thrombocytopenic Purpura in Children
    Naithani, Rahul
    Kumar, Rajat
    Mahapatra, M.
    Tyagi, Seema
    Mishra, Pravas
    INDIAN PEDIATRICS, 2010, 47 (06) : 517 - 519
  • [44] Detection of Anti-D and Anti-G in a Pregnant Woman: A Case Report
    Halim, Sarah Abdul
    Yusoff, Shafini Mohamed
    Abdullah, Marne
    Iberahim, Salfarina
    Zulkafli, Zefarina
    Noor, Noor Haslina Mohd
    Ramli, Marini
    Bahar, Rosnah
    Hasan, Mohd Nazri
    Abd Rahman, Wan Suriana Wan
    GAZI MEDICAL JOURNAL, 2022, 33 (01): : 82 - 84
  • [45] New developments in the biological activity of anti-D monoclonal antibodies
    Kumpel, B. M.
    ISBT SCIENCE SERIES, VOL 2, NO 1: STATE OF THE ART PRESENTATIONS, 2007, 2 (01): : 75 - 77
  • [46] ANTI-D QUANTIFICATION BY FLOW-CYTOMETRY - AN ALTERNATIVE TO THE AUTOANALYZER
    AUSTIN, EB
    MCINTOSH, Y
    HODSON, C
    LEE, D
    TRANSFUSION MEDICINE, 1995, 5 (03) : 203 - 208
  • [47] A review of anti-D treatment of childhood idiopathic thrombocytopenic purpura
    Kjaersgaard, Mimi
    Hasle, Henrik
    PEDIATRIC BLOOD & CANCER, 2006, 47 (05) : 717 - 720
  • [49] Efficacy and safety of anti-D for immune thrombocytopenic purpura in children
    Rahul Naithani
    Rajat Kumar
    M. Mahapatra
    Seema Tyagi
    Pravas Mishra
    Indian Pediatrics, 2010, 47 : 517 - 519
  • [50] Subcutaneous Anti-D Treatment of Idiopathic Thrombocytopenic Purpura in Children
    Kjaersgaard, Mimi
    Edslev, Pernille Wendtland
    Hasle, Henrik
    PEDIATRIC BLOOD & CANCER, 2009, 53 (07) : 1315 - 1317